Cefotetan: Difference between revisions
Gerald Chi (talk | contribs) m (Changed protection level for "Cefotetan" ([Edit=Allow only autoconfirmed users] (expires 15:02, 22 January 2014 (UTC)) [Move=Allow only autoconfirmed users] (expires 15:02, 22 January 2014 (UTC)))) |
No edit summary |
||
Line 1: | Line 1: | ||
__NOTOC__ | |||
{{Cefotetan}} | |||
{{CMG}};{{AE}}{{AK}} | |||
'''''For patient information, click <u>[[Cefotetan Disodium(patient information)|here]]'''''</u> | |||
==Overview== | |||
'''Cefotetan''' is an injectable [[antibiotic]] of the [[cephamycin]] type for prophylaxis and treatment of [[bacterial infection]]s. It is often grouped together with second-generation [[cephalosporin]]s and has a similar antibacterial spectrum, but with additional anti-anaerobe converage. | '''Cefotetan''' is an injectable [[antibiotic]] of the [[cephamycin]] type for prophylaxis and treatment of [[bacterial infection]]s. It is often grouped together with second-generation [[cephalosporin]]s and has a similar antibacterial spectrum, but with additional anti-anaerobe converage. | ||
Cefotetan was developed by [[Yamanouchi]]. It is marketed outside Japan by [[AstraZeneca]] with the brand names '''Apatef''' and '''Cefotan'''. | Cefotetan was developed by [[Yamanouchi]]. It is marketed outside Japan by [[AstraZeneca]] with the brand names '''Apatef''' and '''Cefotan'''. | ||
==Category== | |||
[[Cephalosporins]], second generation. | |||
==US Brand Names== | |||
[[ | CEFOTETAN® | ||
{{ | |||
==FDA Package Insert== | |||
''' [[Cefotetan description|Description]]''' | |||
'''| [[Cefotetan clinical pharmacology|Clinical Pharmacology]]''' | |||
'''| [[Cefotetan microbiology|Microbiology]]''' | |||
'''| [[Cefotetan indications and usage|Indications and Usage]]''' | |||
'''| [[Cefotetan contraindications|Contraindications]]''' | |||
'''| [[Cefotetan warnings and precautions|Warnings and Precautions]]''' | |||
'''| [[Cefotetan adverse reactions|Adverse Reactions]]''' | |||
'''| [[Cefotetan overdosage|Overdosage]]''' | |||
'''| [[Cefotetan clinical studies|Clinical Studies]]''' | |||
'''| [[Cefotetan dosage and administration|Dosage and Administration]]''' | |||
'''| [[Cefotetan Compatibility and Stability|Compatibility and Stability]]''' | |||
'''| [[Cefotetan how supplied|How Supplied]]''' | |||
'''| [[Cefotetan labels and packages|Labels and Packages]]''' | |||
==References== | |||
{{Reflist|2}} | |||
http://www.accessdata.fda.gov/drugsatfda_docs/label/2003/50588slr027_cefotan_lbl.pdf | |||
[[Category:Antibiotics]] | |||
[[Category:Wikinfect]] |
Revision as of 07:23, 10 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: Abdurahman Khalil, M.D. [2] For patient information, click here
Overview
Cefotetan is an injectable antibiotic of the cephamycin type for prophylaxis and treatment of bacterial infections. It is often grouped together with second-generation cephalosporins and has a similar antibacterial spectrum, but with additional anti-anaerobe converage.
Cefotetan was developed by Yamanouchi. It is marketed outside Japan by AstraZeneca with the brand names Apatef and Cefotan.
Category
Cephalosporins, second generation.
US Brand Names
CEFOTETAN®
FDA Package Insert
Description | Clinical Pharmacology | Microbiology | Indications and Usage | Contraindications | Warnings and Precautions | Adverse Reactions | Overdosage | Clinical Studies | Dosage and Administration | Compatibility and Stability | How Supplied | Labels and Packages
References
http://www.accessdata.fda.gov/drugsatfda_docs/label/2003/50588slr027_cefotan_lbl.pdf